The industry, patients, and clinicians should now seek a better understanding of the criteria and conditions, including any potential relationship with the health technology assessment review recommendations and any obligation on the company if DFMO does not successfully navigate the reimbursement process. …
Worth knowing the criteria used to justify the creation of the DFMO 'bridging' fund
July 16, 2024 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News -
Vaxxas appoints former global vaccines leader to head global commercialisation push
January 8, 2026 - - Australian Biotech